Literature DB >> 22983906

Mapping I-A(g7) restricted epitopes in murine G6PC2.

Tao Yang1, Anita C Hohenstein, Catherine E Lee, John C Hutton, Howard W Davidson.   

Abstract

G6PC2, also known as islet-specific glucose 6-phosphatase catalytic subunit-related protein (IGRP), is a major target of autoreactive CD8(+) T cells in both diabetic human subjects and the non-obese diabetic (NOD) mouse. However, in contrast to the abundant literature regarding the CD8(+) response to this antigen, much less is known about the potential involvement of IGRP-reactive CD4(+) T cells in diabetogenesis. The single previous study that examined this question in NOD mice was based upon a candidate epitope approach and identified three I-A(g7)-restricted epitopes that each elicited spontaneous responses in these animals. However, given the known inaccuracies of MHC class II epitope prediction algorithms, we hypothesized that additional specificities might also be targeted. To address this issue, we immunized NOD mice with membranes from insect cells overexpressing full-length recombinant mouse IGRP and measured recall responses of purified CD4(+) T cells using a library of overlapping peptides encompassing the entire 355-aa primary sequence. Nine peptides representing 8 epitopes gave recall responses, only 1 of which corresponded to any of the previously reported sequences. In each case proliferation was blocked by a monoclonal antibody to I-A(g7), but not the appropriate isotype control. Consistent with a role in diabetogenesis, proliferative responses to 4 of the 9 peptides (3 epitopes) were also detected in CD4(+) T cells purified from the pancreatic draining lymph nodes of pre-diabetic female animals, but not from peripheral lymph nodes or spleens of the same animals. Intriguingly, one of the newly identified spontaneously reactive epitopes (P8 [IGRP(55-72)]) is highly conserved between mice and man, suggesting that it might also be a target of HLA-DQ8-restricted T cells in diabetic human subjects, an hypothesis that we are currently testing.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22983906      PMCID: PMC3664523          DOI: 10.1007/s12026-012-8368-5

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  59 in total

Review 1.  A comprehensive review of interventions in the NOD mouse and implications for translation.

Authors:  Lisl K M Shoda; Daniel L Young; Saroja Ramanujan; Chan C Whiting; Mark A Atkinson; Jeffrey A Bluestone; George S Eisenbarth; Diane Mathis; Aldo A Rossini; Scott E Campbell; Richard Kahn; Huub T C Kreuwel
Journal:  Immunity       Date:  2005-08       Impact factor: 31.745

2.  Predicting peptides bound to I-Ag7 class II histocompatibility molecules using a novel expectation-maximization alignment algorithm.

Authors:  Kuan Y Chang; Anish Suri; Emil R Unanue
Journal:  Proteomics       Date:  2007-02       Impact factor: 3.984

Review 3.  Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?

Authors:  Lucienne Chatenoud
Journal:  Nat Rev Endocrinol       Date:  2010-03       Impact factor: 43.330

4.  Identification of novel IGRP epitopes targeted in type 1 diabetes patients.

Authors:  Irene Jarchum; Lynn Nichol; Massimo Trucco; Pere Santamaria; Teresa P DiLorenzo
Journal:  Clin Immunol       Date:  2008-03-20       Impact factor: 3.969

5.  Islet-specific glucose-6-phosphatase catalytic subunit-related protein-reactive CD4+ T cells in human subjects.

Authors:  Junbao Yang; Nancy A Danke; DeAnna Berger; Sandra Reichstetter; Helena Reijonen; Carla Greenbaum; Catherine Pihoker; Eddie A James; William W Kwok
Journal:  J Immunol       Date:  2006-03-01       Impact factor: 5.422

6.  Worldwide childhood type 1 diabetes incidence--what can we learn from epidemiology?

Authors:  G Soltesz; C C Patterson; G Dahlquist
Journal:  Pediatr Diabetes       Date:  2007-10       Impact factor: 4.866

7.  Changes in autoreactive T cell avidity during type 1 diabetes development.

Authors:  Nathan E Standifer; Emily A Burwell; Vivian H Gersuk; Carla J Greenbaum; Gerald T Nepom
Journal:  Clin Immunol       Date:  2009-05-23       Impact factor: 3.969

8.  Beta-cell-cytotoxic CD8+ T cells from nonobese diabetic mice use highly homologous T cell receptor alpha-chain CDR3 sequences.

Authors:  P Santamaria; T Utsugi; B J Park; N Averill; S Kawazu; J W Yoon
Journal:  J Immunol       Date:  1995-03-01       Impact factor: 5.422

9.  A single-nucleotide polymorphism in a methylatable Foxa2 binding site of the G6PC2 promoter is associated with insulin secretion in vivo and increased promoter activity in vitro.

Authors:  Christine Dos Santos; Pierre Bougnères; Delphine Fradin
Journal:  Diabetes       Date:  2008-11-04       Impact factor: 9.461

10.  Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T cells.

Authors:  A Bendelac; C Carnaud; C Boitard; J F Bach
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

View more
  1 in total

1.  Regulatory T Cells Induced by Single-Peptide Liposome Immunotherapy Suppress Islet-Specific T Cell Responses to Multiple Antigens and Protect from Autoimmune Diabetes.

Authors:  Anne-Sophie Bergot; Irina Buckle; Sumana Cikaluru; Jennifer Loaiza Naranjo; Casey Maree Wright; Guoliang Zheng; Meghna Talekar; Emma E Hamilton-Williams; Ranjeny Thomas
Journal:  J Immunol       Date:  2020-02-28       Impact factor: 5.426

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.